UA85527C2 - Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent - Google Patents

Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent

Info

Publication number
UA85527C2
UA85527C2 UA2002075749A UA2002075749A UA85527C2 UA 85527 C2 UA85527 C2 UA 85527C2 UA 2002075749 A UA2002075749 A UA 2002075749A UA 2002075749 A UA2002075749 A UA 2002075749A UA 85527 C2 UA85527 C2 UA 85527C2
Authority
UA
Ukraine
Prior art keywords
antibody
fragment
immunoconjugate
prostate cancer
polypeptide
Prior art date
Application number
UA2002075749A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ричард Харкинс
Дебора Паркес
Гордон Перри
Дуглас В. Шнайдер
Ренате Штейнбрехер
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of UA85527C2 publication Critical patent/UA85527C2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

The invention relates to separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide RG1. Also the invention relates to immunoconjugate that includes separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide RG1. Besides, the invention relates to the method for selective destruction of cell that expresses polypeptide, to the method for prostate cancer providing injection to the patient of therapeutically effective quantity of immunoconjugate, methods of diagnostics of prostate cancer and its metastases in patient using the superexpression RG1 metering. Also the method relates to application of antibody and immunoconjugate as therapeutic agent.
UA2002075749A 1999-12-16 2000-12-15 Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent UA85527C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17237099P 1999-12-16 1999-12-16

Publications (1)

Publication Number Publication Date
UA85527C2 true UA85527C2 (en) 2009-02-10

Family

ID=50556928

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002075749A UA85527C2 (en) 1999-12-16 2000-12-15 Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent

Country Status (1)

Country Link
UA (1) UA85527C2 (en)

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2004032857A8 (en) Antibody therapy
MXPA05012011A (en) Therapeutic use of anti-cs1 antibodies.
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
HK1016018A1 (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
MY150237A (en) Cripto blocking antibodies and uses thereof
DK0528931T3 (en) Humanized chimeric anti-ICAM-1 antibodies, methods for their preparation and their use
DK0942740T3 (en) Combination therapy using a TFN-binding protein to treat TFN-mediated diseases
MY151032A (en) Treatment of tnf? related disorders
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
MXPA04006517A (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours.
GEP20135826B (en) Novel antibodies used to treat cancer
ATE412756T1 (en) METHOD FOR DIAGNOSING CANCER USING A CHIMERIC TOXIN
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2006088464A3 (en) A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
SI1684770T1 (en) Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
PL330705A1 (en) Tie-2 receptor ligands (ligand-3 tie; ligand-4 tie) and their application
DE60238435D1 (en) TARGETED THROMBOSE THROUGH TISSUE FACTOR POLYPEPTIDES
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules